Reversal of antipsychotic-induced hyperprolactinemia, weight gain, hyperglycemia and dyslipidemia by aripiprazole add-on therapy in the treatment of schizophrenia and bipolar disorder: An open-label trial
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- 19 Oct 2007 New trial record.
- 10 Oct 2007 Biomarkers information updated